Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02576574
Registration number
NCT02576574
Ethics application status
Date submitted
13/10/2015
Date registered
15/10/2015
Date last updated
20/03/2024
Titles & IDs
Public title
Avelumab in First-line NSCLC (JAVELIN Lung 100)
Query!
Scientific title
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Query!
Secondary ID [1]
0
0
2015-001537-24
Query!
Secondary ID [2]
0
0
EMR 100070-005
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
First Line Non-Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Avelumab
Treatment: Drugs - Pemetrexed
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Carboplatin
Treatment: Drugs - Cisplatin
Treatment: Drugs - Carboplatin
Treatment: Drugs - Avelumab Weekly
Experimental: Avelumab Biweekly -
Experimental: Avelumab Weekly -
Active Comparator: Chemotherapy -
Treatment: Drugs: Avelumab
Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
Treatment: Drugs: Pemetrexed
Participants received Pemetrexed 500 milligrams per square meter (mg/m^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
Treatment: Drugs: Paclitaxel
Participants received Paclitaxel 200 mg/m^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
Treatment: Drugs: Gemcitabine
Participants received Gemcitabine 1250 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
Treatment: Drugs: Gemcitabine
Participants received Gemcitabine 1000 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
Treatment: Drugs: Carboplatin
Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
Treatment: Drugs: Cisplatin
Participants received Cisplatin 75 mg/m^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
Treatment: Drugs: Carboplatin
Carboplatin AUC 6 mg/mL*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
Treatment: Drugs: Avelumab Weekly
Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)
Query!
Assessment method [1]
0
0
PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [1]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Primary outcome [2]
0
0
Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS)
Query!
Assessment method [2]
0
0
PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [2]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Primary outcome [3]
0
0
Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)
Query!
Assessment method [3]
0
0
OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [3]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Primary outcome [4]
0
0
Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)
Query!
Assessment method [4]
0
0
OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [4]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)
Query!
Assessment method [1]
0
0
PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [1]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [2]
0
0
Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)
Query!
Assessment method [2]
0
0
PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [2]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [3]
0
0
Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)
Query!
Assessment method [3]
0
0
OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [3]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [4]
0
0
Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)
Query!
Assessment method [4]
0
0
OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [4]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [5]
0
0
Overall Survival (OS) in Full Analysis Set (FAS)
Query!
Assessment method [5]
0
0
OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [5]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [6]
0
0
Overall Survival (OS) in Modified Full Analysis Set (mFAS)
Query!
Assessment method [6]
0
0
OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [6]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Full Analysis Set
Query!
Assessment method [7]
0
0
Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Query!
Timepoint [7]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Modified Full Analysis Set
Query!
Assessment method [8]
0
0
Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Query!
Timepoint [8]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Full Analysis Set
Query!
Assessment method [9]
0
0
Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Query!
Timepoint [9]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Modified Full Analysis Set
Query!
Assessment method [10]
0
0
Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Query!
Timepoint [10]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [11]
0
0
Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)
Query!
Assessment method [11]
0
0
DOR was defined for participants with confirmed response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Query!
Timepoint [11]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [12]
0
0
Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)
Query!
Assessment method [12]
0
0
DOR was defined for participants with confirmed response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Query!
Timepoint [12]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [13]
0
0
Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High PD-L1+ Health-related Quality of Life (HRQoL) Analysis Set at End of Treatment
Query!
Assessment method [13]
0
0
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
Query!
Timepoint [13]
0
0
Baseline, End of treatment (up to Week 283.9)
Query!
Secondary outcome [14]
0
0
Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set
Query!
Assessment method [14]
0
0
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
Query!
Timepoint [14]
0
0
Baseline, End of treatment (Week 283.9)
Query!
Secondary outcome [15]
0
0
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set
Query!
Assessment method [15]
0
0
EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.
Query!
Timepoint [15]
0
0
Baseline, End of treatment (up to Week 283.9)
Query!
Secondary outcome [16]
0
0
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set
Query!
Assessment method [16]
0
0
EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.
Query!
Timepoint [16]
0
0
Baseline, End of treatment (Week 283.9)
Query!
Secondary outcome [17]
0
0
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set
Query!
Assessment method [17]
0
0
EORTC QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The EORTC QLQ-LC13 module generated one multiple-item score assessing dyspnea and a series of single item scores assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arms or shoulder and pain in other parts. Score range: 0 (no burden of symptom domain or single symptom item) to 100 (highest burden of symptoms for symptom domains and single items).
Query!
Timepoint [17]
0
0
Baseline, End of treatment (up to Week 283.9)
Query!
Secondary outcome [18]
0
0
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set
Query!
Assessment method [18]
0
0
EORTC QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The EORTC QLQ-LC13 module generated one multiple-item score assessing dyspnea and a series of single item scores assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arms or shoulder and pain in other parts. Score range: 0 (no burden of symptom domain or single symptom item) to 100 (highest burden of symptoms for symptom domains and single items).
Query!
Timepoint [18]
0
0
Baseline, End of treatment (up to Week 283.9)
Query!
Secondary outcome [19]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and AEs of Special Interest (AESIs)
Query!
Assessment method [19]
0
0
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAEs were those events with onset dates occurring during the on-treatment period or if the worsening of an event is during the on-treatment period TEAEs included both serious TEAEs and non-serious TEAEs. Any AE that was suspicious to be a potential Immune-related adverse event (irAE) including infusion related reactions were considered AESIs. Number of participants with TEAEs and AESIs were reported.
Query!
Timepoint [19]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [20]
0
0
Number of Participants With Shift From Baseline to Greater Than or Equal to (>=) Grade 3 in Laboratory Parameter Values Based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03
Query!
Assessment method [20]
0
0
Number of participants with shifts from Baseline values (Grade 0/1/2/3) to abnormal post-baseline values (shift to >= Grade 4) were reported as per NCI-CTCAE, v4.03 graded from Grade 1 to 5. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death. Shifts in laboratory parameter (anemia, lymphocyte count decreased, neutrophil count decreased, platelet count decreased, white blood cell count decreased, alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase increased, creatinine increased and Hyperglycemia) were reported.
Query!
Timepoint [20]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [21]
0
0
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Body Temperature Increase
Query!
Assessment method [21]
0
0
The number of participants with changes from baseline in increased Body Temperature (degree Celsius [°C]) were reported by using criteria: Baseline temperature (temp.) less than (<) 37°C, on treatment change <1°C, 1 - <2°C, 2 - <3°C, greater than or equal to (>=)3°C and missing; Baseline temp. 37 - <38°C, on treatment change <1°C, 1 - <2°C, 2 - <3°C, >=3°C and missing; Baseline temp. 38 - <39°C, on treatment change <1°C, 1 - <2°C, 2 - <3°C, >=3°C and missing; Baseline temp. 39-<40°C, on treatment change <1°C, 1 - <2°C, 2 - <3°C, >=3°C and missing; Baseline temp. >=40°C, on treatment change <1°C, 1 - <2°C, 2 - <3°C, >=3°C and missing; Baseline temp. missing, on treatment change missing.
Query!
Timepoint [21]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [22]
0
0
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Weight Increase/Decrease
Query!
Assessment method [22]
0
0
The number of participants with maximal on-treatment changes from baseline in Increase (Ic.)/Decrease (Dc.) in maximal weight were reported by using criteria: Ic./Dc. From baseline, on treatment (TR) change <10 percentage (%), >=10% and missing.
Query!
Timepoint [22]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [23]
0
0
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Heart Rate Increase/Decrease
Query!
Assessment method [23]
0
0
The number of participants with maximal on-treatment (TR) changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) heart rate (HR) (beats per minute [bpm]) were reported by using criteria: Ic./Dc. BS HR <100/>=100 bpm, on treatment change =<20 bpm, >20 - =<40 bpm, >40 bpm and missing; Ic./Dc. BS HR missing, on treatment change missing.
Query!
Timepoint [23]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [24]
0
0
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Systolic Blood Pressure Increase/Decrease and Maximal Diastolic Blood Pressure Increase/Decrease
Query!
Assessment method [24]
0
0
The number of participants with maximal on-treatment changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) Systolic Blood Pressure (SBP) and diastolic blood pressure (DBP) (millimeter of mercury [mmHg]) were reported by using criteria: Ic./Dc. BS SBP <140 mmHg and >=140 mmHg, on maximal treatment (TR) change =<20 mmHg, >20 - =<40 mmHg, >40 mmHg and missing; Ic./Dc. BS SBP missing, on maximal treatment (TR) change missing; Ic./Dc. BS DBP <90 mmHg and >= 90 mmHg, on maximal TR change =<20 mmHg, >20 - =<40 mmHg, >40 mmHg and missing; Ic./Dc. BS DBP missing on maximal TR change missing.
Query!
Timepoint [24]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [25]
0
0
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Respiration Rate Increase/Decrease
Query!
Assessment method [25]
0
0
The number of participants with maximal on-treatment (TR) changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) maximal Respiration Rate (RR) were reported by using criteria: Ic./Dc. BS RR <20 breaths per minute (breaths/min), on TR change =<5 breaths/min, >5 - =<10 breaths/min, >10 breaths/min and missing. Ic./Dc. BS RR missing, on TR change missing. Ic./Dc. BS RR >=20 breaths/min, on TR change =<5 breaths/min, >5 - =<10 breaths/min, >10 breaths/min and missing.
Query!
Timepoint [25]
0
0
Time from date of randomization up to data cutoff (assessed up to 71.5 months)
Query!
Secondary outcome [26]
0
0
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Electrocardiogram (ECG) Parameters
Query!
Assessment method [26]
0
0
ECG parameters included heart rate, PR interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). PCSA criteria for abnormal value of ECG parameters: any heart rate <= 50 bpm and decrease from baseline >=20 bpm , any hear rate >= 120 bpm and increase from baseline >= 20 bpm; PR interval: >= 220 milliseconds (ms) and increase from baseline >= 20 ms; QRS interval >= 120 ms; QTcF > 450 ms, > 480 ms, > 500 ms, QTcF increase from baseline > 30 ms and QTcF increase from baseline > 60 ms; QTcB > 450 ms, > 480 ms, > 500 ms, QTcB increase from baseline > 30 ms and QTcB increase from baseline > 60 ms.
Query!
Timepoint [26]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [27]
0
0
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score Versus (Vs) Worst Post-baseline Score
Query!
Assessment method [27]
0
0
ECOG performance status measured to assess participant's performance status on a scale of 0 to 5, where 0 = Fully active, able to carry on all pre-disease activities without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out light or sedentary work; 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; 3 = Capable of only limited self-care, confined to bed/chair for more than 50 percent of waking hours; 4 = Completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5 = dead. ECOG performance status was reported in terms of number of participants with baseline value vs worst post-baseline value (that is [i.e.] highest score).
Query!
Timepoint [27]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Secondary outcome [28]
0
0
Number of Participants With At Least One Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Avelumab
Query!
Assessment method [28]
0
0
Serum samples were analyzed by a validated electrochemiluminesce immunoassay to detect the presence of antidrug antibodies (ADA). Samples that screened positive were subsequently tested in a confirmatory assay were tested for neutralizing antibodies (nAb). Number of participants with ADA or nAb positive results for Avelumab were reported.
Query!
Timepoint [28]
0
0
Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
Query!
Eligibility
Key inclusion criteria
- Male or female subjects aged greater than or equal to (>=) 18 years
- With Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at
trial entry
- At least 1 measurable tumor lesion
- With histologically confirmed metastatic or recurrent (Stage IV) non-small cell lung
cancer (NSCLC)
- With availability of a recently-obtained, formalin-fixed, paraffin-embedded (FFPE)
tissue sample containing tumor (biopsy from a non-irradiated area preferably within 6
months) or a minimum number of 10 (preferably 25) unstained tumor slides cut within 1
week, and suitable for PD-L1 expression assessment
- Subjects must not have received any treatment for systemic lung cancer, and have an
estimated life expectancy of more than 12 weeks
- Other protocol defined criteria could apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects whose disease harbors a EGFR mutation, or anaplastic lymphoma kinase (ALK)
rearrangement are not eligible.
- Other exclusion criteria include prior therapy with any antibody or drug targeting T
cell coregulatory proteins, concurrent anticancer treatment, or immunosuppressive
agents
- Known severe hypersensitivity reactions to monoclonal antibodies (Grade >= 3 NCI CTCAE
v 4.03), history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features
of partially controlled asthma), and persisting toxicity related to prior therapy of
Grade > 1 NCI-CTCAE v 4.03.
- Subjects with brain metastases are excluded, except those meeting the following
criteria: brain metastases that have been treated locally and are clinically stable
for at least 2 weeks prior to randomization, subjects must be either off steroids or
on a stable or decreasing dose of <= 10 mg daily prednisone (or equivalent), and do
not have ongoing neurological symptoms that are related to the brain localization of
the disease.
- Other protocol defined criteria could apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/10/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
29/01/2024
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1214
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Albury Wodonga Regional Cancer Centre - Albury
Query!
Recruitment hospital [2]
0
0
Coffs Harbour Health Campus - Coffs Harbour
Query!
Recruitment hospital [3]
0
0
St George Private Hospital - Kogarah
Query!
Recruitment hospital [4]
0
0
Lismore Base Hospital - Lismore
Query!
Recruitment hospital [5]
0
0
Orange Health Service - Orange
Query!
Recruitment hospital [6]
0
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [7]
0
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment hospital [8]
0
0
Gallipoli Medical Research Foundation Ltd - Greenslopes
Query!
Recruitment hospital [9]
0
0
Gold Coast University Hospital - Southport
Query!
Recruitment hospital [10]
0
0
The Queen Elizabeth Hospital - Woodville South
Query!
Recruitment hospital [11]
0
0
Ballarat Base Hospital - Ballarat
Query!
Recruitment hospital [12]
0
0
Bendigo Hospital - Bendigo
Query!
Recruitment hospital [13]
0
0
South West Healthcare - Warrnambool
Query!
Recruitment hospital [14]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2640 - Albury
Query!
Recruitment postcode(s) [2]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [3]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [4]
0
0
2480 - Lismore
Query!
Recruitment postcode(s) [5]
0
0
2800 - Orange
Query!
Recruitment postcode(s) [6]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [7]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [8]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [9]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [10]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [11]
0
0
3350 - Ballarat
Query!
Recruitment postcode(s) [12]
0
0
3550 - Bendigo
Query!
Recruitment postcode(s) [13]
0
0
3280 - Warrnambool
Query!
Recruitment postcode(s) [14]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Montana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nevada
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Mexico
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oklahoma
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Vermont
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Wyoming
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Antwerpen
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Brasschaat
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Mons
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
Bahia
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Ceará
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Goiás
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Paraná
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Rio Grande Do Sul
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Santa Catarina
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Sao Paulo
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Rio de Janeiro
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Ruse
Query!
Country [32]
0
0
Bulgaria
Query!
State/province [32]
0
0
Sofia
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
New Brunswick
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Chile
Query!
State/province [35]
0
0
Santiago
Query!
Country [36]
0
0
Chile
Query!
State/province [36]
0
0
Viña del Mar
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Beijing
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Guangdong
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Heilongjiang
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Liaoning
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Shandong
Query!
Country [42]
0
0
Colombia
Query!
State/province [42]
0
0
Bogotá
Query!
Country [43]
0
0
Colombia
Query!
State/province [43]
0
0
Floridablanca
Query!
Country [44]
0
0
Colombia
Query!
State/province [44]
0
0
Medellín
Query!
Country [45]
0
0
Colombia
Query!
State/province [45]
0
0
Monteria
Query!
Country [46]
0
0
Croatia
Query!
State/province [46]
0
0
Zagreb
Query!
Country [47]
0
0
Cyprus
Query!
State/province [47]
0
0
Nicosia
Query!
Country [48]
0
0
Czechia
Query!
State/province [48]
0
0
Liberec
Query!
Country [49]
0
0
Czechia
Query!
State/province [49]
0
0
Nova Ves pod Plesi
Query!
Country [50]
0
0
Czechia
Query!
State/province [50]
0
0
Olomouc
Query!
Country [51]
0
0
Czechia
Query!
State/province [51]
0
0
Ostrava - Vitkovice
Query!
Country [52]
0
0
Czechia
Query!
State/province [52]
0
0
Praha 4 - Krc
Query!
Country [53]
0
0
Czechia
Query!
State/province [53]
0
0
Usti nad Labem
Query!
Country [54]
0
0
Denmark
Query!
State/province [54]
0
0
Herning
Query!
Country [55]
0
0
Denmark
Query!
State/province [55]
0
0
Roskilde
Query!
Country [56]
0
0
Estonia
Query!
State/province [56]
0
0
Tallinn
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Alpes Maritimes
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Bas Rhin
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Bouches-du-Rhône
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Doubs
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Finistere
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Gironde
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Maine Et Loire
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Paris
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Pyrenees Atlantiques
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Rhone
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Sarthe
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Vaculuse
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Val De Marne
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Paris Cedex 10
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Baden Wuerttemberg
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Schleswig Holstein
Query!
Country [73]
0
0
Greece
Query!
State/province [73]
0
0
Athens
Query!
Country [74]
0
0
Greece
Query!
State/province [74]
0
0
Heraklion
Query!
Country [75]
0
0
Greece
Query!
State/province [75]
0
0
Patras
Query!
Country [76]
0
0
Greece
Query!
State/province [76]
0
0
Thessaloniki
Query!
Country [77]
0
0
Hungary
Query!
State/province [77]
0
0
Budapest
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Deszk
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Györ
Query!
Country [80]
0
0
Hungary
Query!
State/province [80]
0
0
Miskolc
Query!
Country [81]
0
0
Hungary
Query!
State/province [81]
0
0
Nyiregyhaza
Query!
Country [82]
0
0
Hungary
Query!
State/province [82]
0
0
Szekszard
Query!
Country [83]
0
0
Hungary
Query!
State/province [83]
0
0
Torokbalint
Query!
Country [84]
0
0
Hungary
Query!
State/province [84]
0
0
Zalaegerszeg
Query!
Country [85]
0
0
Ireland
Query!
State/province [85]
0
0
Cork
Query!
Country [86]
0
0
Israel
Query!
State/province [86]
0
0
Beer Sheva
Query!
Country [87]
0
0
Israel
Query!
State/province [87]
0
0
Haifa
Query!
Country [88]
0
0
Israel
Query!
State/province [88]
0
0
Jerusalem
Query!
Country [89]
0
0
Israel
Query!
State/province [89]
0
0
Kfar-Saba
Query!
Country [90]
0
0
Israel
Query!
State/province [90]
0
0
Petach Tikva
Query!
Country [91]
0
0
Israel
Query!
State/province [91]
0
0
Ramat Gan
Query!
Country [92]
0
0
Israel
Query!
State/province [92]
0
0
Rechovot
Query!
Country [93]
0
0
Israel
Query!
State/province [93]
0
0
Rishon Lezion
Query!
Country [94]
0
0
Israel
Query!
State/province [94]
0
0
Tel Aviv
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Verona
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Brescia
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Catania
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Genova
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Napoli
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Parma
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Pisa
Query!
Country [102]
0
0
Japan
Query!
State/province [102]
0
0
Chiba-Ken
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Fukuoka-Ken
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Hokkaido
Query!
Country [105]
0
0
Japan
Query!
State/province [105]
0
0
Hyogo-Ken
Query!
Country [106]
0
0
Japan
Query!
State/province [106]
0
0
Kanagawa-Ken
Query!
Country [107]
0
0
Japan
Query!
State/province [107]
0
0
Osaka-Fu
Query!
Country [108]
0
0
Japan
Query!
State/province [108]
0
0
Tokyo-To
Query!
Country [109]
0
0
Japan
Query!
State/province [109]
0
0
Toyama-Ken
Query!
Country [110]
0
0
Japan
Query!
State/province [110]
0
0
Kobe-shi
Query!
Country [111]
0
0
Korea, Republic of
Query!
State/province [111]
0
0
Chungcheongbuk-do
Query!
Country [112]
0
0
Korea, Republic of
Query!
State/province [112]
0
0
Gangwon-do
Query!
Country [113]
0
0
Korea, Republic of
Query!
State/province [113]
0
0
Gyeonggi-do
Query!
Country [114]
0
0
Korea, Republic of
Query!
State/province [114]
0
0
Daegu
Query!
Country [115]
0
0
Korea, Republic of
Query!
State/province [115]
0
0
Incheon
Query!
Country [116]
0
0
Korea, Republic of
Query!
State/province [116]
0
0
Seoul
Query!
Country [117]
0
0
Korea, Republic of
Query!
State/province [117]
0
0
Ulsan
Query!
Country [118]
0
0
Lebanon
Query!
State/province [118]
0
0
Beirut
Query!
Country [119]
0
0
Lebanon
Query!
State/province [119]
0
0
Saida
Query!
Country [120]
0
0
Lithuania
Query!
State/province [120]
0
0
Kaunas
Query!
Country [121]
0
0
Netherlands
Query!
State/province [121]
0
0
Groningen
Query!
Country [122]
0
0
Netherlands
Query!
State/province [122]
0
0
Hoorn
Query!
Country [123]
0
0
Netherlands
Query!
State/province [123]
0
0
Tilburg
Query!
Country [124]
0
0
New Zealand
Query!
State/province [124]
0
0
Auckland
Query!
Country [125]
0
0
New Zealand
Query!
State/province [125]
0
0
Dunedin
Query!
Country [126]
0
0
New Zealand
Query!
State/province [126]
0
0
Hamilton
Query!
Country [127]
0
0
New Zealand
Query!
State/province [127]
0
0
Palmerston North
Query!
Country [128]
0
0
New Zealand
Query!
State/province [128]
0
0
Tauranga
Query!
Country [129]
0
0
New Zealand
Query!
State/province [129]
0
0
Wellington
Query!
Country [130]
0
0
Peru
Query!
State/province [130]
0
0
Lima
Query!
Country [131]
0
0
Poland
Query!
State/province [131]
0
0
Lodz
Query!
Country [132]
0
0
Poland
Query!
State/province [132]
0
0
Lublin
Query!
Country [133]
0
0
Poland
Query!
State/province [133]
0
0
Mrozy
Query!
Country [134]
0
0
Poland
Query!
State/province [134]
0
0
Olsztyn
Query!
Country [135]
0
0
Poland
Query!
State/province [135]
0
0
Otwock
Query!
Country [136]
0
0
Poland
Query!
State/province [136]
0
0
Poznan
Query!
Country [137]
0
0
Poland
Query!
State/province [137]
0
0
Szklarska Poreba
Query!
Country [138]
0
0
Poland
Query!
State/province [138]
0
0
Warszawa
Query!
Country [139]
0
0
Poland
Query!
State/province [139]
0
0
Wieliszew
Query!
Country [140]
0
0
Portugal
Query!
State/province [140]
0
0
Almada
Query!
Country [141]
0
0
Portugal
Query!
State/province [141]
0
0
Amadora-Lisbon
Query!
Country [142]
0
0
Portugal
Query!
State/province [142]
0
0
Coimbra
Query!
Country [143]
0
0
Portugal
Query!
State/province [143]
0
0
Lisboa
Query!
Country [144]
0
0
Portugal
Query!
State/province [144]
0
0
Porto
Query!
Country [145]
0
0
Portugal
Query!
State/province [145]
0
0
Santa Maria da Feira
Query!
Country [146]
0
0
Portugal
Query!
State/province [146]
0
0
Vila Nova de Gaia
Query!
Country [147]
0
0
Romania
Query!
State/province [147]
0
0
Baia Mare
Query!
Country [148]
0
0
Romania
Query!
State/province [148]
0
0
Brasov
Query!
Country [149]
0
0
Romania
Query!
State/province [149]
0
0
Bucuresti
Query!
Country [150]
0
0
Romania
Query!
State/province [150]
0
0
Cluj Napoca
Query!
Country [151]
0
0
Romania
Query!
State/province [151]
0
0
Cluj-Napoca
Query!
Country [152]
0
0
Romania
Query!
State/province [152]
0
0
Comuna Floresti
Query!
Country [153]
0
0
Romania
Query!
State/province [153]
0
0
Constanta
Query!
Country [154]
0
0
Romania
Query!
State/province [154]
0
0
Craiova
Query!
Country [155]
0
0
Romania
Query!
State/province [155]
0
0
Iasi
Query!
Country [156]
0
0
Romania
Query!
State/province [156]
0
0
Oradea
Query!
Country [157]
0
0
Romania
Query!
State/province [157]
0
0
Suceava
Query!
Country [158]
0
0
Romania
Query!
State/province [158]
0
0
Timisoara
Query!
Country [159]
0
0
Russian Federation
Query!
State/province [159]
0
0
Arkhangelsk
Query!
Country [160]
0
0
Russian Federation
Query!
State/province [160]
0
0
Chelyabinsk
Query!
Country [161]
0
0
Russian Federation
Query!
State/province [161]
0
0
Irkutsk
Query!
Country [162]
0
0
Russian Federation
Query!
State/province [162]
0
0
Ivanovo
Query!
Country [163]
0
0
Russian Federation
Query!
State/province [163]
0
0
Kaluga
Query!
Country [164]
0
0
Russian Federation
Query!
State/province [164]
0
0
Kazan
Query!
Country [165]
0
0
Russian Federation
Query!
State/province [165]
0
0
Kemerovo
Query!
Country [166]
0
0
Russian Federation
Query!
State/province [166]
0
0
Krasnoyarsk
Query!
Country [167]
0
0
Russian Federation
Query!
State/province [167]
0
0
Kursk
Query!
Country [168]
0
0
Russian Federation
Query!
State/province [168]
0
0
Moscow
Query!
Country [169]
0
0
Russian Federation
Query!
State/province [169]
0
0
Murmansk
Query!
Country [170]
0
0
Russian Federation
Query!
State/province [170]
0
0
Novosibirsk
Query!
Country [171]
0
0
Russian Federation
Query!
State/province [171]
0
0
Pyatigorsk
Query!
Country [172]
0
0
Russian Federation
Query!
State/province [172]
0
0
Saint-Petersburg
Query!
Country [173]
0
0
Russian Federation
Query!
State/province [173]
0
0
Samara
Query!
Country [174]
0
0
Russian Federation
Query!
State/province [174]
0
0
Sochi
Query!
Country [175]
0
0
Russian Federation
Query!
State/province [175]
0
0
St. Petersburg
Query!
Country [176]
0
0
Russian Federation
Query!
State/province [176]
0
0
Tomsk
Query!
Country [177]
0
0
Russian Federation
Query!
State/province [177]
0
0
Tyumen
Query!
Country [178]
0
0
Russian Federation
Query!
State/province [178]
0
0
Yaroslavl
Query!
Country [179]
0
0
Serbia
Query!
State/province [179]
0
0
Belgrade
Query!
Country [180]
0
0
Serbia
Query!
State/province [180]
0
0
Gornji Matejevac
Query!
Country [181]
0
0
Serbia
Query!
State/province [181]
0
0
Kragujevac
Query!
Country [182]
0
0
Serbia
Query!
State/province [182]
0
0
Sremska Kamenica
Query!
Country [183]
0
0
Singapore
Query!
State/province [183]
0
0
Singapore
Query!
Country [184]
0
0
Slovakia
Query!
State/province [184]
0
0
Bardejov
Query!
Country [185]
0
0
Slovakia
Query!
State/province [185]
0
0
Bratislava
Query!
Country [186]
0
0
South Africa
Query!
State/province [186]
0
0
Gauteng
Query!
Country [187]
0
0
South Africa
Query!
State/province [187]
0
0
Western Cape
Query!
Country [188]
0
0
Spain
Query!
State/province [188]
0
0
Barcelona
Query!
Country [189]
0
0
Spain
Query!
State/province [189]
0
0
Guipuzcoa
Query!
Country [190]
0
0
Spain
Query!
State/province [190]
0
0
La Coruña
Query!
Country [191]
0
0
Spain
Query!
State/province [191]
0
0
Pontevedra
Query!
Country [192]
0
0
Spain
Query!
State/province [192]
0
0
Girona
Query!
Country [193]
0
0
Spain
Query!
State/province [193]
0
0
Madrid
Query!
Country [194]
0
0
Spain
Query!
State/province [194]
0
0
Málaga
Query!
Country [195]
0
0
Spain
Query!
State/province [195]
0
0
Sevilla
Query!
Country [196]
0
0
Spain
Query!
State/province [196]
0
0
Vitoria
Query!
Country [197]
0
0
Taiwan
Query!
State/province [197]
0
0
Kaohsiung
Query!
Country [198]
0
0
Taiwan
Query!
State/province [198]
0
0
Taichung
Query!
Country [199]
0
0
Taiwan
Query!
State/province [199]
0
0
Taipei
Query!
Country [200]
0
0
Taiwan
Query!
State/province [200]
0
0
Taoyuan County
Query!
Country [201]
0
0
Thailand
Query!
State/province [201]
0
0
Bangkok
Query!
Country [202]
0
0
Thailand
Query!
State/province [202]
0
0
Chiang Mai
Query!
Country [203]
0
0
Thailand
Query!
State/province [203]
0
0
Khon Kaen
Query!
Country [204]
0
0
Thailand
Query!
State/province [204]
0
0
Phitsanulok
Query!
Country [205]
0
0
Thailand
Query!
State/province [205]
0
0
Songkhla
Query!
Country [206]
0
0
Turkey
Query!
State/province [206]
0
0
Adana
Query!
Country [207]
0
0
Turkey
Query!
State/province [207]
0
0
Ankara
Query!
Country [208]
0
0
Turkey
Query!
State/province [208]
0
0
Antalya
Query!
Country [209]
0
0
Turkey
Query!
State/province [209]
0
0
Istanbul
Query!
Country [210]
0
0
Turkey
Query!
State/province [210]
0
0
Izmir
Query!
Country [211]
0
0
Turkey
Query!
State/province [211]
0
0
Malatya
Query!
Country [212]
0
0
Turkey
Query!
State/province [212]
0
0
Mersin
Query!
Country [213]
0
0
Turkey
Query!
State/province [213]
0
0
Sakarya
Query!
Country [214]
0
0
Turkey
Query!
State/province [214]
0
0
Tekirdag
Query!
Country [215]
0
0
Ukraine
Query!
State/province [215]
0
0
Chernivtsi
Query!
Country [216]
0
0
Ukraine
Query!
State/province [216]
0
0
Dnipro
Query!
Country [217]
0
0
Ukraine
Query!
State/province [217]
0
0
Ivano-Frankivsk
Query!
Country [218]
0
0
Ukraine
Query!
State/province [218]
0
0
Kharkiv
Query!
Country [219]
0
0
Ukraine
Query!
State/province [219]
0
0
Kherson
Query!
Country [220]
0
0
Ukraine
Query!
State/province [220]
0
0
Kropyvnytskyi
Query!
Country [221]
0
0
Ukraine
Query!
State/province [221]
0
0
Kryvyi Rih, Dnipropetrovsk Region
Query!
Country [222]
0
0
Ukraine
Query!
State/province [222]
0
0
Kyiv
Query!
Country [223]
0
0
Ukraine
Query!
State/province [223]
0
0
Lutsk
Query!
Country [224]
0
0
Ukraine
Query!
State/province [224]
0
0
Lviv
Query!
Country [225]
0
0
Ukraine
Query!
State/province [225]
0
0
Odesa
Query!
Country [226]
0
0
Ukraine
Query!
State/province [226]
0
0
Sumy
Query!
Country [227]
0
0
Ukraine
Query!
State/province [227]
0
0
Uzhgorod
Query!
Country [228]
0
0
Ukraine
Query!
State/province [228]
0
0
Vinnytsia
Query!
Country [229]
0
0
United Kingdom
Query!
State/province [229]
0
0
Essex
Query!
Country [230]
0
0
United Kingdom
Query!
State/province [230]
0
0
Gloucestershire
Query!
Country [231]
0
0
United Kingdom
Query!
State/province [231]
0
0
Greater London
Query!
Country [232]
0
0
United Kingdom
Query!
State/province [232]
0
0
Hertfordshire
Query!
Country [233]
0
0
United Kingdom
Query!
State/province [233]
0
0
Merseyside
Query!
Country [234]
0
0
United Kingdom
Query!
State/province [234]
0
0
Staffordshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
EMD Serono Research & Development Institute, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Merck KGaA, Darmstadt, Germany
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS)
or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an
Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants
with Programmed death ligand 1+ (PD-L1+) tumors.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02576574
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Responsible
Query!
Address
0
0
EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02576574
Download to PDF